MACROGENICS INC (MGNX) Stock Price & Overview
NASDAQ:MGNX • US5560991094
The current stock price of MGNX is 3.12 USD. Today MGNX is down by -6.59%. In the past month the price increased by 81.4%. In the past year, price increased by 40.54%.
MGNX Key Statistics
- Market Cap
- 197.371M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.18
- Dividend Yield
- N/A
MGNX Stock Performance
MGNX Stock Chart
MGNX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MGNX. When comparing the yearly performance of all stocks, MGNX is one of the better performing stocks in the market, outperforming 95.87% of all stocks.
MGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MGNX. Both the profitability and financial health of MGNX have multiple concerns.
MGNX Earnings
On March 9, 2026 MGNX reported an EPS of -0.23 and a revenue of 31.54M. The company beat EPS expectations (22.41% surprise) and beat revenue expectations (36.56% surprise).
MGNX Forecast & Estimates
13 analysts have analysed MGNX and the average price target is 3.47 USD. This implies a price increase of 11.15% is expected in the next year compared to the current price of 3.12.
For the next year, analysts expect an EPS growth of -65.1% and a revenue growth -50.75% for MGNX
MGNX Groups
Sector & Classification
MGNX Financial Highlights
Over the last trailing twelve months MGNX reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS decreased by -9.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.05% | ||
| ROE | -134.23% | ||
| Debt/Equity | 1.26 |
MGNX Ownership
MGNX Latest News, Press Relases and Analysis
MGNX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 398.492B | ||
| AMGN | AMGEN INC | 16.11 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.5 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MGNX
Company Profile
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 341 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Company Info
IPO: 2013-10-10
MACROGENICS INC
9704 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Scott Koenig
Employees: 341
Phone: 13012515172
MACROGENICS INC / MGNX FAQ
Can you describe the business of MACROGENICS INC?
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 341 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
What is the stock price of MACROGENICS INC today?
The current stock price of MGNX is 3.12 USD. The price decreased by -6.59% in the last trading session.
Does MGNX stock pay dividends?
MGNX does not pay a dividend.
What is the ChartMill rating of MACROGENICS INC stock?
MGNX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy MGNX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MGNX.
How many employees does MACROGENICS INC have?
MACROGENICS INC (MGNX) currently has 341 employees.
What is MACROGENICS INC worth?
MACROGENICS INC (MGNX) has a market capitalization of 197.37M USD. This makes MGNX a Micro Cap stock.